An estimated 750,000 individuals in the United States have hypertrophic cardiomyopathy (HCM), and up to 20 million worldwide when genetic studies are extrapolated to populations. HCM is a genetically derived heart disease characterized by an overly thick left ventricle with a generally normal ejection fraction.

This resource, supported through an unrestricted grant from Bristol Myers Squibb, provides general information about HCM and its nonpharmacological and pharmacological treatment.

Access Resource